Literature DB >> 25956155

Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection.

Jennifer L Garber1, Katie L Willenborg, Anne E Rose.   

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. Traditionally, warfarin has been used to prevent the occurrence of stroke in intermediate-to-high risk patients. Target-specific oral anticoagulants (TSOACs) have become a favorable alternative; however, recommendations for differentiating between the available TSOACs were lacking within the 2012 CHEST guidelines. The objective of this retrospective, observational study was to identify current anticoagulation prescribing habits in patients admitted with new-onset AF, and evaluate the appropriateness of discharge therapy based on national guidelines. Additionally, a practice guideline was created for use at our institution to stratify appropriate use of TSOACs. Patients were included if they were at least 18 years old and were admitted with a primary diagnosis of new-onset, non-valvular AF between July 1, 2012 and June 30, 2013. CHADS2, CHA2DS2VASc, and HAS-BLED scores were calculated based on patient data. Between July 2012 and June 2013, 143 patients were included in the study. The average CHADS2 score was 1.7, the average CHA2DS2VASc score was 3.0, and the average HAS-BLED score was 2.4. The use of no antithrombotics decreased as the CHA2DS2VASc score increased, aspirin use stayed consistent across risk groups, warfarin use increased as the CHA2DS2VASc score increased, and TSOAC use decreased with increasing CHA2DS2VASc score. A total of 34 % of study patients were prescribed inappropriate treatment upon discharge, based on national guidelines. This study demonstrated that patients admitted to our hospital were prescribed appropriate therapy the majority of the time; however, 34 % were prescribed inadequate antithrombotic therapy compared to current practice guidelines given their CHA2DS2VASc score. The development of an institution-specific guideline stratifying appropriate use of anticoagulation in this population may increase adherence to national guideline recommendations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25956155     DOI: 10.1007/s11239-015-1223-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  16 in total

1.  Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)).

Authors:  Geoffrey D Barnes; Scott Kaatz; Julia Winfield; Xiaokui Gu; Brian Haymart; Eva Kline-Rogers; Jay Kozlowski; Dennis Beasley; Steve Almany; Tom Leyden; James B Froehlich
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

3.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Christian Torp-Pedersen; Morten Lock Hansen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2012-04-03       Impact factor: 5.249

4.  Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors:  John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

5.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

6.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

7.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  Thromb Haemost       Date:  2011-07-20       Impact factor: 5.249

Review 8.  Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.

Authors:  Salvatore Rosanio; Abdul M Keylani; Darrin C D'Agostino; Craig M DeLaughter; Antonio Vitarelli
Journal:  Int J Cardiol       Date:  2014-04-26       Impact factor: 4.164

9.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

10.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Authors:  Jonathan Mant; F D Richard Hobbs; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; Ellen Murray
Journal:  Lancet       Date:  2007-08-11       Impact factor: 79.321

View more
  5 in total

1.  A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.

Authors:  Joshua D Brown; Anand R Shewale; Parinita Dherange; Jeffery C Talbert
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

2.  Inappropriate prescribing of antithrombotic therapy in Ethiopian elderly population using updated 2015 STOPP/START criteria: a cross-sectional study.

Authors:  Henok Getachew; Akshaya Srikanth Bhagavathula; Tamrat Befekadu Abebe; Sewunet Admasu Belachew
Journal:  Clin Interv Aging       Date:  2016-06-20       Impact factor: 4.458

3.  Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.

Authors:  Sergio Agosti; Laura Casalino; Enrico Rocci; Gabriele Zaccone; Eugenia Rota
Journal:  J Med Case Rep       Date:  2017-08-15

4.  Development and validation of hospital information system-generated indicators of the appropriateness of oral anticoagulant prescriptions in hospitalised adults: the PACHA study protocol.

Authors:  Aurélie Petit-Monéger; Frantz Thiessard; Vianney Jouhet; Pernelle Noize; Driss Berdaï; Marion Kret; Rémi Sitta; Louis-Rachid Salmi; Florence Saillour-Glénisson
Journal:  BMJ Open       Date:  2017-08-31       Impact factor: 2.692

5.  Appropriate use of anti-thrombotic therapy in patients with atrial fibrillation at single-center experience, Northwest Ethiopia.

Authors:  Ermiyas Endewunet; Abilo Tadesse; Aynishet Adane; Mohamed Abdulkadir
Journal:  BMC Cardiovasc Disord       Date:  2020-08-17       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.